Kempen European Life Sciences M&A update

Bi-monthly update on Mergers & Acquisitions of European Life Sciences companies

Provides insights on the current M&A climate, recent developments, transactions and other relevant insights in the field of M&A

Example analysis from the July 2018 M&A update below

Sellers’ market in European Life Sciences M&A leads to highest premiums in over 6 years

Buyers of European Life Sciences companies* have recently paid significantly higher premiums versus the stable 2012-2016 period

The number of transactions is similarly increasing over recent years, with 2018 set to continue this trend

With a premium of 120%, Sanofi paid 2018’s highest premium so far when acquiring Belgian biotech company Ablynx * Based on announced European Life Sciences transactions with a European target If the transaction was rumoured before, the non-disturbed share price applies